Malaria Vaccines Market Anticipated to Reach USD 1,619.87 Million by 2034

The global malaria vaccines market was valued at USD 491.90 million in 2024 and is projected to grow from USD 553.63 million in 2025 to reach approximately USD 1,619.87 million by 2034. This growth is expected to occur at a compound annual growth rate (CAGR) of 12.7% during the forecast period from 2025 to 2034. The increasing incidence of malaria, particularly in sub-Saharan Africa and other endemic regions, is a key factor driving the demand for effective malaria vaccines. Rising public health initiatives and advancements in vaccine development are further fueling market expansion.Market Definition:

The malaria vaccines market focuses on the development, production, and distribution of vaccines aimed at preventing malaria infections. Increasing efforts to reduce malaria-related mortality, especially in endemic regions, drive market growth. Advancements in biotechnology and funding from global health organizations are accelerating vaccine development. Regulatory approvals and public immunization programs are key growth factors. The launch of new-generation vaccines is expected to transform disease control strategies.

Key Report Highlights:

Based on vaccine type, the RTS,S/AS01 segment held the largest share of the malaria vaccines market revenue in 2024, owing to the extensive clinical research and trials demonstrating the efficacy of RTS, S/AS01 vaccines, and their rollout in various African countries.
By administration route, the intramuscular segment led the malaria vaccines market share in 2024 as intramuscular is the most widely used route for administrating malaria vaccines, including R21/Matrix-M and RTS,S/AS01.
North America led the market for malaria vaccines in 2024, driven by the strong presence of leading pharma companies with significant investments in malaria vaccine development programs and the introduction of favorable government regulations supporting malaria vaccine R&D initiatives.
The Middle East & Africa malaria vaccines market is projected to witness a significant CAGR from 2025 to 2034, driven by the rising focus on improving healthcare infrastructure and enhanced collaborations between government and private organizations to develop cost-effective malaria vaccines.

Market Overview: Key Figures at a Glance

Market Value in 2024: USD 491.90 million
Projected Market Size in 2034: USD 1,619.87 million
Anticipated CAGR 2025-2034: 12.7%

𝐆𝐞𝐭 𝐄𝐱𝐜𝐥𝐮𝐬𝐢𝐯𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐚𝐠𝐞𝐬 𝐨𝐟 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭:

https://www.polarismarketresearch.com/industry-analysis/malaria-vaccines-market/request-for-sample

Market Growth Drivers:

Growing Prevalence of Malaria in Low-Income Countries:

Malaria cases continue to rise globally, especially in tropical and low-income regions.
According to WHO, malaria cases increased from 252 million in 2022 to 263 million in 2023, with 597,000 deaths.
The disease is most prevalent in Africa, Asia, South America, and the Western Pacific regions.
Climate change is creating more favorable conditions for mosquito vectors, worsening the spread.
This growing burden in vulnerable regions is driving demand for effective malaria vaccines.

Increasing Funding and Investment:

Public and private sector funding is accelerating malaria vaccine development and innovation.
International organizations, governments, and private investors are backing large-scale research efforts.
Increased investment is fostering competition and supporting mass production and distribution.
Funding ensures vaccines reach high-risk populations, strengthening global health responses and fueling market growth.

Market Key Players:

The competitive landscape features a mix of long-standing companies and emerging contenders. Leading players are actively pursuing R&D initiatives and strategic moves to strengthen their market position. Notable participants include